On the 18F–fluoride PET imaging quantification to predict 223Ra-dichloride treatment response

  • Eric Laffon
  • Henri de Clermont
  • Roger Marthan
  • Fredéric Paycha
Letter to the Editor
  • 228 Downloads

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Research involving human participants and/or animals

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

The ethics committees of our teaching hospitals approved this retrospective study and the requirement to obtain further informed consent of the example patient was waived.

References

  1. 1.
    Murray I, Chittenden SJ, Denis-Bacelar AM, Hindorf C, Parker CC, Chua S, et al. The potential of 223Ra and 18F-fluoride imaging to predict bone lesion response to treatment with 223Ra-dichloride in castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2017;  https://doi.org/10.1007/s00259-017-3744-y.
  2. 2.
    Lin C, Bradshaw TJ, Perk TG, Harmon S, Eickhoff J, Jallow N, et al. Repeatability of quantitative 18F-NaF PET: a multicenter study. J Nucl Med. 2016;57:1872–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Laffon E, Lamare F, de Clermont H, Burger IA, Marthan R. Variability of average SUV from several hottest voxels is lower than that of SUVmax and SUVpeak. Eur Radiol. 2014;24:1964–70.CrossRefPubMedGoogle Scholar
  4. 4.
    Caubet O, Meunier V, Marthan R, Laffon E. Early assessment of treatment response in Takayasu arteritis: an 18FDG PET procedure. Clin Nucl Med. 2016;41:743–5.CrossRefPubMedGoogle Scholar
  5. 5.
    Lodge MA. Repeatability of SUV in oncologic 18F-FDG PET. J Nucl Med. 2017;58:523–32.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Etchebehere EC, Araujo JC, Fox PS, Swanston NM, Macapinlac HA, Rohren EM. Prognostic factors in patients treated with 223Ra: the role of skeletal tumor burden on baseline 18F-fluoride PET/CT in predicting overall survival. J Nucl Med. 2015;56:1177–84.CrossRefPubMedGoogle Scholar
  7. 7.
    JCGM. Evaluation of measurement data - guide to the expression of uncertainty in measurement. 2008; www.bipm.org, Sept 2008.
  8. 8.
    Kurdziel KA, Shih JH, Apolo AB, Lindenberg L, Mena E, McKinney Y, et al. The kinetics and reproducibility of 18F-sodium fluoride for oncology using current PET camera technology. J Nucl Med. 2012;53:1175–84.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  1. 1.CHU de BordeauxBordeauxFrance
  2. 2.Univ. Bordeaux, Centre de Recherche Cardio-Thoracique de BordeauxBordeauxFrance
  3. 3.INSERM U-1045, Centre de Recherche Cardio-Thoracique de BordeauxBordeauxFrance
  4. 4.Service de Médecine Nucléaire, Hôpital Lariboisiere, Assistance Publique-Hôpitaux de ParisParis Cedex 10France

Personalised recommendations